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A B S T R A CT  
Coronavirus or COVID-19 is started from the China, Wuhan city in December 2019 and soon later, 
spread around 190 countries and declared as pandemic on March 11, 2020 by WHO. Healthcare 
systems all over the world are fighting against this pandemic. Most of the countries are lockdown for 
uncertain periods to protect their people from this pandemic as a result the world economy is struggling 
to cope up with the current situation. Several countries have conducted research studies to produce 
vaccine or antiviral drug but there is still no specific solution for the prevention or treatment of 
COVID-19 infection in general. Along with other treatment methods, many countries are fuelling their 
demand for antiviral compounds from natural resources due to coronavirus. Microalgae and 
cyanobacteria are excellent source of antiviral activity. Several cyclic or linear peptides and 
depsipeptides isolated from cyanobacteria are protease inhibitors, which is considered as significant 
antiviral candidate. Micro and macroalgae were one of the first sources of natural compounds showing 
in vitro anti-HIV activity. Numerous in vitro or in vivo studies has shown the potential of algae against 
wild range of viruses. The use of natural products in the manufacturing of drugs is an ancient and well-
established practice. Marine microorganisms are known producers of pharmacological and anti-viral 
agents and may provide unlimited biological resources to produce therapeutic drugs for the treatment 
and control of viral diseases in humans. Our major intention to write this review to bring world’s 
attention in terms of public health and public policy practices across the world to grab an opportunity 
from this known healthcare practices, and conventional platform to produce vaccine or antiviral 
medicine to overcome COID-19. 
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1 Introduction 
The coronavirus 2 (SARS-CoV-2) or severe acute respiratory syndrome was first identified in a few rare 
pneumonia patients linked to the Wuhan seafood wholesale market in China in December 2019 (Chen et 
al., 2020; Gorbalenva et al., 2020). Soon later, the corona virus disease 2019 (COVID-19) spread all around 
the world listed 190 countries and was declared a pandemic on March 11, 2020 (WHO report, 2020). The 
whole world’s healthcare systems are struggling to overcome this pandemic. (WHO report 2020). Due to 
mandatory isolation or quarantines, millions of lives have been affected seriously. The current effect of the 
COVID-19 outbreak have brought far reaching consequences on the global economy if spread is not 
controlled in time (Gorbaleva, et al., 2020; Kupferschmidt, et al., 2020; Corona report). Coronaviruses 
infect both humans and animals, bats are the major mammals that host the largest variety of coronaviruses 
appear to be immune to coronavirus-induced illness. (Anthony, et al., 2017). The worlds medical systems 
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are working hard and fast to control this pandemic by each means, since there are no specific treatments 
for CoV infection and preventive vaccines are still being explored.  
Algae is the major component of any water bodies, ocean, rivers, estuaries etc. Both marine and fresh water 
algae, cyanobacteria, diatoms have certain crucial compounds that can be effective or act as inhibitory 
against many viruses. For this pandemic coronavirus numerous research activities are on-going worldwide 
and the studies have shown that protease inhibitors, which make up the major part of plant derivatives can 
therefore be very effective in controlling virus-induced infection. The recent study on eight secondary 
metabolites from conventional medicinal plants on COVID-19 virus protease were performed by using 
molecular docking analysis. The outcome of the study says that, the compounds investigated can interact 
with major amino acids in the enzyme flap to inhibit the new coronavirus protease enzyme. Among these 
secondary metabolites, Curcumin, the secondary metabolite of turmeric has the strongest interaction with 
the protease enzyme COVID-19. (Mohammadi, et al., 2020).  
Blue green algae, Cyanobacteria has protease inhibitors which are very effective against antiviruses. Several 
cyclic or linear peptides and depsipeptides isolated from cyanobacteria are protease inhibitors, used for the 
treatment of diseases such as strokes, coronary artery occlusions and pulmonary emphysema (Skulberg, 
2004; Singh et al., 2005). Micro and macroalgae were one of the first sources of natural compounds showing 
in vitro anti-HIV activity (Schaeffer and Krylov, 2000). The antibacterial activity of an aquatic microalgae 
was first reported for Chlorella vulgaris (Pratt and Fong, 1940). An early report of the antimicrobial properties 
of seaweed extracts was published a decade later (Pratt et al., 1951), and several other papers appeared in 
the next two decades (Burkholder and Sharma, 1969). This published literature and their results highlights 
the significance of algae as antiviral, antibacterial and antimicrobial activities. The present review will 
highlight some of the antiviral activities of algae, which is one of the vast aquatic organisms and which can 
help in controlling the present pandemic COVID-19. Many countries are looking for some of the strategies 
or organisms containing antiviral compounds or activities to develop vaccines or antiviral drugs and 
sanitisers to control this extreme situation. This review could help to the ongoing research efforts on 
COVID-19, public health and public policy practices across the world. 
2 Literature Review & Discussion 
2.1 Antiviral Activities of Algae 
Microalgae and cyanobacteria are excellent source of antiviral activity. Silva et al., 2018 have shown in his 
study that, more than 80% inhibition of seasonal influenza A and B replication in MDCK cells occurred 
from seven extracts derived from microalgae and cyanobacteria in ethyl acetate solvent. Two extracts from 
Leptolyngbya sp. (cyanobacteria) and Chlorellaceae family (microalgae) inhibited influenza A and B 
replication and neuraminidase activity, from OST-sensitive and resistance strains and lineages. Thus, these 
organisms are important for bioprospecting in antiviral research. Similarly, Algae-derived polysaccharides 
were successfully introduced by Gerber and et al., 1958 as an antiviral agent. They found significant 
inhibition of mumps and Influenza B virus. Later, red algae polysaccharide fractions were tested as a potent 
source of antiviral agents against HSV and other viruses in the next two decades. Since then, numerous 
studies have published for the antiviral potential of various algae-derived polysaccharides. Red macro algae 
like Kappaphycus alvarezii, Hypnea musciformis (carrageenophytes) (Picture 1) cell wall contains sulphated 
polysaccharides has similar property like porphydium as a potential antiviral drug. (Burkholder & Sharma, 
1969; Deig et al., 1974; Ehresmann et al., 1977; Richards et al., 1978, Reddy et.al., 2003; Reddy et al., 2005 
(US patent); Gaikwad et al., 2009). 
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Picture 1: Macro algae A. Hypnea musciformis B. Kappaphycus alvarezii, Macroalgae cultivation methods  
C. In plastic bags, D. in nylon bags (Reddy et.al., 2003; 2005) 
Table 1: Antivirals derived from marine algae (Lu et al., 2010) 
Compound Common 
name 
Organism Virus Reference 
A1  Microalgae Cochlodinium 
polykrikoides 
Influenza virus A and B; RSV A and B; HSV-
1 
Hasui et al. 
(1995) 
A2 Microalgae Cochlodinium 
polykrikoides 
Influenza virus A and B; RSV A and B; 
parainfluenza type 2 
Hasui et al. 
(1995) 
AcDa-1  Dictyota 
menstrualis 
HIV-1 replication and RNA-dependent DNA 
polymerase 
activity of the viral RT 
Pereira et al. 
(2004) 
Calcium 
spirulan 
Cynobacteria Arthrospira 
platensis 
(previously called 
Spirulina platensis) 
HSV-1 replication; Measles replication; 
Mumps replication; 
Influenza replication; Polio replication; 
Coxsackie replication; 
HIV-1 replication; HCMV replication; 
Selectively inhibition of 
penetration into host cells 
Hayashi et al. 
(1996) 
Cyanovirin-N 
Da-1 
Cynobacteria Nostoc 
ellipsosporum 
HIV-1 and HIV-2 and SIV fusion, replication 
and CPE 
HIV-1 replication and RNA-dependent DNA 
polymerase 
activity of the viral RT 
Boyd et al. 
(1996) 
Pereira et al. 
(2004) 
Fucoidan Brown 
seaweed 
Fucus vesiculosus HSV-1 and HSV-2; HCMV; VSV; Sinbis 
virus; HIV-1 RT 
Béress et al. 
(1993), Moen 
and Clark 
(1993) 
Galactan 
Sulfate 
Red seaweed Agardhiella tenera HIV-1 and HIV-1 CPE and syncytia 
formation; HIV-1 binding to 
host cells; Binding of anti-gpl20 mAb to HIV-
1 gpl20; Other 
enveloped viruses (herpes viruses, 
togaviruses, arenaviruses, 
etc.) 
Witvrouw et 
al. (1994) 
Griffithsin Red alga Griffithsia sp. HIV-1 glycoproteins (e.g., gpl20, gp41 and 
gpl60) 
Mori et al. 
(2005) 
Naviculan Diatom Navicula directa HSV-1 and HSV-2 adhesion, penetration and 
replication 
Lee et al. 
(2006) 
SAE Red alga  Schizymenia 
pacifca 
HIV RT; AMV RT; RMLV RT Nakashima et 
al. (1987a, b) 
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2.2 Future Prospectus of Marine Antiviral Drugs 
Numerous in vitro or in vivo studies has shown the potential of algae against wild range of viruses (Table 
1). The use of natural products in the manufacturing of drugs is an ancient and well-established practice 
(Roussis, 2005). Marine microorganisms are known producers of pharmacological and anti-viral agents and 
may provide unlimited biological resources to produce therapeutic drugs for the treatment and control of 
viral diseases in humans, livestock and marine farming species, as well as ever more novel compounds. 
(Bhadury et al., 2006).  
However, due to lack of enough knowledge in terms of micro and macro algae cultivation pharmaceutical 
industries have discouraged from pursuing commercialization of marine-derived bioactive molecules. So 
far, these industries have focussed their research on limited organisms (Tziveleka et al., 2003), especially 
whichever is available near shores or collected seasonally or randomly. Along with large scale cultivation of 
marine algae for the large-scale production of these compounds for the clinical trials, drug development, 
combinatorial genetics and metabolic engineering could be the future solution for commercial production 
of these compounds. Another important challenge, as with any antiviral drugs, will be the development of 
resistance by various viruses. However, when considering the numerous undiscovered organisms in the 
marine environment, along with their unique metabolites, it is probable that increasing numbers of novel 
drugs will be discovered that viruses have not yet developed resistance to. It is also important to note that 
many organisms of different species produce similar classes of compounds, each suited for their unique 
composition and living environment. The fact that varying derivatives of a common class of compound are 
being produced by multiple organisms may be a solution. A virus that has developed resistance to a typical 
drug may not be resistant to other naturally occurring derivatives, which have the potential to possess 
similar, if not identical, antiviral activities. Should no alternatives be found occurring in nature, the 
application of biochemical technologies will allow the manipulation of naturally occurring compounds to 
produce chemical derivatives that are far superior to the original (Bhadury et al., 2006).  
2.3 Status of Research and Development Centre, Reliance Industries Limited  
Reliance Industries Research and Development center has its diverse germplasm repository of algal 
strains.  Reliance biology R & D team is continuously running 20-acre open pond algae facility (Picture 2) 
last from few years, without crash. This huge algae cultivation facility is unique in the world and the 
produced algal biomass can 
be utilized for the 
pharmaceutical production 
of different drugs including 
antivirals with appropriate 
regulatory approval. 
 
 
 
 
 
 
Picture 2: Reliance algae cultivation facility 
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3 Conclusion  
To the best of our knowledge, Microalgae and cyanobacteria are excellent source of antiviral activity. Several 
cyclic or linear peptides and depsipeptides isolated from cyanobacteria are protease inhibitors, which is 
considered as significant antiviral candidate. Micro and macroalgae were one of the first sources of natural 
compounds showing in vitro anti-HIV activity. Numerous in vitro or in vivo studies has shown the potential 
of algae against wild range of viruses. The use of natural products in the manufacturing of drugs is an 
ancient and well-established practice. Marine microorganisms are known producers of pharmacological and 
anti-viral agents and may provide unlimited biological resources to produce therapeutic drugs for the 
treatment and control of viral diseases in humans and probably in recent pandemic, COVID-19.  
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